Amedisys Stock Price Target and Analyst Ratings (NASDAQ:AMED)

Analyst Price Target for AMED

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$274.46

▲ +12.29% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $274.46, with a high forecast of $340.00 and a low forecast of $190.00. The average price target represents a 12.29% upside from the last price of $244.43.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Amedisys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/15/2019

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/14/2019

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/13/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/11/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/9/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/8/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/6/2021

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/8/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/1/2021	Benchmark	Boost Price Target	Buy	$275.00 ➝ $325.00	N/A	i
2/23/2021	Benchmark	Boost Price Target	Positive ➝ Buy	$275.00 ➝ $325.00	Medium	i
2/8/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$275.00 ➝ $340.00	Medium	i
1/5/2021	Truist	Boost Price Target		$280.00 ➝ $325.00	N/A	i
11/3/2020	Barclays	Boost Price Target	Overweight	$290.00 ➝ $298.00	Medium	i
10/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$260.00 ➝ $275.00	High	i
10/30/2020	Credit Suisse Group	Boost Price Target	Outperform	$246.00 ➝ $280.00	High	i
9/21/2020	Oppenheimer	Boost Price Target	Outperform	$250.00 ➝ $260.00	High	i
9/10/2020	Stephens	Reiterated Rating	Equal Weight	$235.00 ➝ $245.00	Medium	i
9/2/2020	BMO Capital Markets	Boost Price Target	Market Perform	$250.00 ➝ $270.00	High	i
8/20/2020	Barclays	Initiated Coverage	Overweight	$290.00 ➝ $290.00	High	i
7/30/2020	SunTrust Banks	Boost Price Target	Buy	$260.00 ➝ $270.00	Medium	i
7/30/2020	Benchmark	Boost Price Target	Buy	$210.00 ➝ $250.00	Medium	i Rating by Bill Sutherland at Benchmark Co.
7/30/2020	Royal Bank of Canada	Boost Price Target	Outperform	$218.00 ➝ $260.00	Medium	i
7/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$220.00 ➝ $260.00	Medium	i
7/30/2020	Raymond James	Boost Price Target	Outperform	$210.00 ➝ $255.00	Medium	i
7/29/2020	Jefferies Financial Group	Boost Price Target	Buy	$225.00 ➝ $250.00	Medium	i
7/10/2020	SunTrust Banks	Boost Price Target	Buy	$240.00 ➝ $260.00	Medium	i
6/18/2020	Benchmark	Upgrade	Hold ➝ Buy	$210.00	High	i
5/21/2020	SunTrust Banks	Boost Price Target	Buy	$225.00 ➝ $240.00	High	i
5/11/2020	UBS Group	Lower Price Target	Neutral	$208.00 ➝ $190.00	Low	i
5/11/2020	Raymond James	Lower Price Target	Outperform	$225.00 ➝ $210.00	Medium	i
5/10/2020	Royal Bank of Canada	Reiterated Rating	Buy	$218.00	Medium	i
5/7/2020	Benchmark	Downgrade	Buy ➝ Hold		High	i
4/27/2020	Oppenheimer	Reiterated Rating	Buy	$215.00	Medium	i
3/9/2020	Benchmark	Upgrade	Hold ➝ Buy	$205.00	High	i
2/21/2020	Stephens	Boost Price Target	Equal Weight	$180.00 ➝ $200.00	Low	i Rating by Scott Fidel at Stephens
2/21/2020	UBS Group	Boost Price Target	Neutral	$154.00 ➝ $208.00	Low	i
2/21/2020	BMO Capital Markets	Reiterated Rating	Market Perform	$215.00	Low	i Rating by Matthew Borsch at BMO Capital Markets
2/21/2020	Credit Suisse Group	Boost Price Target	Outperform	$206.00 ➝ $214.00	Low	i Rating by A.J. Rice at Credit Suisse Group AG
2/20/2020	SunTrust Banks	Boost Price Target	Buy	$185.00 ➝ $225.00	Low	i
2/20/2020	Raymond James	Boost Price Target	Outperform	$200.00 ➝ $225.00	Low	i
1/17/2020	Credit Suisse Group	Initiated Coverage	Outperform	$206.00	Low	i
1/3/2020	Raymond James	Set Price Target	Outperform	$144.00 ➝ $200.00	Medium	i
12/18/2019	SunTrust Banks	Boost Price Target	Buy	$175.00 ➝ $185.00	Low	i
12/6/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$170.00	Medium	i
11/26/2019	Bank of America	Boost Price Target	Buy	$170.00 ➝ $178.00	Low	i
11/1/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$140.00 ➝ $160.00	High	i
10/22/2019	Stephens	Reiterated Rating	Equal Weight	$145.00	Low	i
10/21/2019	Stephens	Initiated Coverage	Equal Weight	$145.00	Low	i
9/16/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$155.00	Low	i
8/5/2019	Barclays	Boost Price Target	Equal Weight	$120.00 ➝ $125.00	High	i
8/2/2019	Royal Bank of Canada	Boost Price Target	Outperform	$150.00	Low	i
8/1/2019	Oppenheimer	Boost Price Target		$140.00 ➝ $150.00	Low	i
7/15/2019	Raymond James	Boost Price Target	Outperform	$140.00 ➝ $144.00	Medium	i
7/8/2019	Jefferies Financial Group	Set Price Target	Buy	$150.00	Low	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
5/2/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$140.00	High	i
3/21/2019	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$115.00 ➝ $120.00	Low	i
3/1/2019	Craig Hallum	Lower Price Target	Hold	$132.00 ➝ $124.00	Low	i
3/1/2019	SunTrust Banks	Boost Price Target	Buy	$145.00	Low	i
2/5/2019	Benchmark	Downgrade	Buy ➝ Hold	$136.64	High	i Rating by Bill Sutherland at Benchmark Co.
12/14/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$130.00	High	i
11/16/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$126.00	Medium	i
10/30/2018	Benchmark	Upgrade	Hold ➝ Buy	$125.00	High	i Rating by Bill Sutherland at Benchmark Co.
10/26/2018	Craig Hallum	Downgrade	Buy ➝ Hold	$116.00 ➝ $104.00	Medium	i
10/11/2018	Robert W. Baird	Boost Price Target	Neutral	$105.00 ➝ $120.00	High	i
10/11/2018	SunTrust Banks	Boost Price Target	Buy	$130.00	High	i
10/11/2018	Cantor Fitzgerald	Boost Price Target	Neutral	$117.00 ➝ $125.00	High	i Rating by J. France at Cantor Fitzgerald
9/18/2018	Bank of America	Set Price Target	Buy	$139.00	Low	i Rating by Joanna Gajuk at Bank of America Co.
9/13/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$117.00	Low	i Rating by J. France at Cantor Fitzgerald
9/13/2018	Canaccord Genuity	Initiated Coverage	Neutral	$117.00	Low	i
8/3/2018	Royal Bank of Canada	Boost Price Target	Outperform	$115.00	Medium	i
7/3/2018	Bank of America	Upgrade	Neutral ➝ Buy	$88.00 ➝ $97.00	Medium	i Rating by Joanna Gajuk at Bank of America Co.
6/5/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$73.00 ➝ $78.00	Medium	i
6/5/2018	Stephens	Reiterated Rating	Hold	$78.00	High	i Rating by Dana Hambly at Stephens
6/5/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$67.00 ➝ $72.00	High	i Rating by Whit Mayo at Robert W. Baird
5/9/2018	Craig Hallum	Boost Price Target	Buy	$60.00 ➝ $82.00	Low	i
5/8/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$66.00	High	i Rating by Whit Mayo at Robert W. Baird
3/19/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform		Low	i
3/1/2018	Robert W. Baird	Set Price Target	Neutral ➝ Hold	$60.00 ➝ $66.00	Medium	i Rating by Whit Mayo at Robert W. Baird
3/1/2018	Oppenheimer	Boost Price Target	Outperform	$68.00 ➝ $63.00	High	i
2/28/2018	Jefferies Financial Group	Set Price Target	Buy	$70.00	Medium	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
11/21/2017	William Blair	Reiterated Rating	Outperform		N/A	i Rating by M. Larew at William Blair
11/10/2017	SunTrust Banks	Reiterated Rating	Buy	$70.00	N/A	i
11/10/2017	Robert W. Baird	Boost Price Target	Neutral	$50.00 ➝ $60.00	N/A	i
11/9/2017	Craig Hallum	Reiterated Rating	Buy	$55.00 ➝ $68.00	N/A	i
11/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$56.00 ➝ $62.00	N/A	i
11/9/2017	Benchmark	Reiterated Rating	Buy ➝ Hold		N/A	i
11/8/2017	Mizuho	Reiterated Rating	Buy	$55.00 ➝ $65.00	N/A	i Rating by Sheryl Skolnick at Mizuho
11/2/2017	Benchmark	Upgrade	Hold ➝ Buy	$56.00	N/A	i
11/2/2017	Mizuho	Upgrade	Neutral ➝ Buy	$55.00 ➝ $65.00	N/A	i Rating by Sheryl Skolnick at Mizuho
10/23/2017	Royal Bank of Canada	Reiterated Rating	Hold		N/A	i
10/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	N/A	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/9/2017	SunTrust Banks	Reiterated Rating	Buy	$60.00	N/A	i
10/4/2017	Robert W. Baird	Reiterated Rating	Hold	$50.00	Low	i
9/15/2017	Oppenheimer	Reiterated Rating	Buy	$60.00	Low	i
8/21/2017	Bank of America	Initiated Coverage	Neutral ➝ Neutral	$55.00	Low	i
7/26/2017	Mizuho	Downgrade	Buy ➝ Neutral	$50.00	High	i Rating by Sheryl Skolnick at Mizuho
6/5/2017	Royal Bank of Canada	Reiterated Rating	Hold	$56.00	Low	i
5/4/2017	Stephens	Boost Price Target	Equal Weight	$50.00 ➝ $54.00	Low	i
5/3/2017	Benchmark	Reiterated Rating	Hold ➝ Hold	$50.00 ➝ $57.00	High	i
5/3/2017	Mizuho	Upgrade	Neutral ➝ Buy	$65.00	High	i Rating by Sheryl Skolnick at Mizuho
4/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$57.00	Low	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/3/2017	Oppenheimer	Reiterated Rating	Outperform	$50.00 ➝ $59.00	N/A	i
3/1/2017	Jefferies Financial Group	Boost Price Target	Buy	$50.00 ➝ $57.00	N/A	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/1/2017	Mizuho	Boost Price Target	Neutral ➝ Neutral	$33.00 ➝ $50.00	N/A	i
1/27/2017	Benchmark	Initiated Coverage	Hold	$50.00	N/A	i
1/17/2017	Craig Hallum	Set Price Target	Buy	$60.00	N/A	i Rating by William Bonello at Craig Hallum
1/13/2017	Jefferies Financial Group	Set Price Target	Buy	$50.00	N/A	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
12/16/2016	Craig Hallum	Initiated Coverage	Buy	$48.00	N/A	i
11/9/2016	Mizuho	Downgrade	Buy ➝ Neutral		N/A	i
11/7/2016	Mizuho	Upgrade	Neutral ➝ Buy	$47.00	N/A	i
11/4/2016	Mizuho	Upgrade	Neutral ➝ Buy	$47.00	N/A	i
11/1/2016	Jefferies Financial Group	Reiterated Rating	Buy	$59.00 ➝ $50.00	N/A	i
9/11/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i
9/6/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
8/3/2016	Mizuho	Downgrade	Buy ➝ Neutral	$57.00 ➝ $55.00	N/A	i Rating by Sheryl Skolnick at Mizuho
6/16/2016	Stephens	Initiated Coverage	Equal Weight	$55.00	N/A	i
5/25/2016	Jefferies Financial Group	Reiterated Rating	Buy	$59.00	N/A	i
5/16/2016	Robert W. Baird	Reiterated Rating	Hold		N/A	i
5/6/2016	Royal Bank of Canada	Boost Price Target	Sector Perform	$41.00 ➝ $48.00	N/A	i
5/4/2016	Oppenheimer	Reiterated Rating	Buy	$56.00	N/A	i Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
4/11/2016	Mizuho	Reiterated Rating	Buy	$49.00 ➝ $57.00	N/A	i
3/17/2016	Oppenheimer	Reiterated Rating	Outperform	$45.00	N/A	i Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
3/11/2016	Mizuho	Reiterated Rating	Buy	$49.00	N/A	i
3/10/2016	Jefferies Financial Group	Reiterated Rating	Buy	$48.00	N/A	i
3/10/2016	Oppenheimer	Reiterated Rating	Outperform	$40.00 ➝ $45.00	N/A	i Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.

(Data available from 3/9/2016 forward)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Today's Range

Now: $244.43

$237.81

$251.10

50 Day Range

MA: $287.27

$236.62

$314.16

52 Week Range

Now: $244.43

$132.95

$325.12

Volume

435,840 shs

Average Volume

183,080 shs

Market Capitalization

$8.03 billion

P/E Ratio

48.98

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, SunTrust Banks, Inc., Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

13 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $274.46, suggesting a possible upside of 12.3%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting AMED will reach $340.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $190.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMED will outperform the market and that investors should add to their positions of Amedisys.
View the latest ratings for AMED.

What other companies compete with Amedisys?

Other companies that are similar to Amedisys include Laboratory Co. of America, Quest Diagnostics, DaVita, Chemed, R1 RCM, LHC Group, AMN Healthcare Services, MEDNAX, CorVel, The Providence Service, Tivity Health, Cross Country Healthcare and Interpace Biosciences.

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is 225-292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com.

NASDAQ:AMED - Amedisys Stock Price Target and Predictions

Analyst Price Target for AMED

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

What is the current price target for Amedisys?

What is the current consensus analyst rating for Amedisys?

What other companies compete with Amedisys?

How do I contact Amedisys' investor relations team?